Annovis Bio has completed the enrolment of patients in a record nine months from the initiation of its Phase III study of its lead compound buntanetap to treat Parkinson's Disease (PD).

The placebo-controlled, randomised, double-blind study will evaluate the tolerability, safety, and efficacy of buntanetap in early PD patients along with the standard of care.

Out of 640 patients screened, a total of 520 patients were enrolled from 24 sites in the EU and 43 sites in the US.

Buntanetap, which is taken once daily, showed improvements in body and motor function in PD patients assessed in Phase I/II studies. The drug was also well tolerated and safe.

The study is anticipated to be completed this November with top-line assessment data to be announced by the year's end.

Annovis founder, president and CEO Maria Maccecchini said: “The Parkinson's community is extremely well-informed and connected.

“When they learned of our innovative and patient-focused approach showing early therapeutic potential they wanted to be involved in making an impact.”

Buntanetap, which was previously known as Posiphen or ANVS401, lowers several neurotoxic proteins thereby improving axonal transport and synaptic transmission in PD patients.

It also improves motor and cognitive dysfunction, lowers inflammation as well as fosters the health of nerve cells.

In addition to PD treatment, Annovisintends to treat dysfunctions of the body and brain caused due to PD, as well as dementia and memory loss associated with Alzheimer's.